TORONTO -- General manager Alex Anthopoulos has no concerns regarding outfielder Melky Cabrera, who last week was linked to a clinic in Miami that allegedly supplied a number of Major League players with performance-enhancing drugs.
The report in the Miami New Times listed Cabrera, who tested positive for elevated levels of testosterone last season and served a 50-game suspension, among other players as clients of Biogenesis, a clinic that has reportedly distributed PEDs to a number of Major Leaguers over the last few years.
Anthopoulos believes there will be no further discipline levied against Cabrera despite the findings in the paper, which trace Cabrera's involvement with the clinic back to 2009.
"It's not news for us. With a report like that, the concern for any club, I would say, is if there was a player that hadn't had any suspensions and that it was a new name," Anthopoulos said. "From that standpoint, it's exactly the same as what we knew before we signed him.
"He served his suspension, we did our work, and I don't expect any changes."
Anthopoulos said he has not spoken to Cabrera or MLB officials regarding the allegations.
The Blue Jays signed Cabrera to a two-year, $16 million deal in the offseason to be the club's starting left fielder and hit out of the two-hole, behind newly acquired leadoff man Jose Reyes.
Before his suspension, Cabrera, 28, led the National League with a .346 batting average and finished the season with career highs in on-base percentage (.390), slugging (.516) and OPS (.906).